TISIDB

Summary
Symbol	NLRC5
Name	NLR family, CARD domain containing 5
Aliases	NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location	16q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm
Domain	PF12799 Leucine Rich repeats (2 copies) PF13516 Leucine Rich repeat
Function	Probable regulator of the NF-kappa-B and type I interferon signaling pathways. May also regulate the type II interferon signaling pathway. Plays a role in homeostatic control of innate immunity and in antiviral defense mechanisms.

> Gene Ontology [ TOP ]
Biological Process	GO:0001818 negative regulation of cytokine production GO:0001959 regulation of cytokine-mediated signaling pathway GO:0001960 negative regulation of cytokine-mediated signaling pathway GO:0001961 positive regulation of cytokine-mediated signaling pathway GO:0002683 negative regulation of immune system process GO:0009615 response to virus GO:0031348 negative regulation of defense response GO:0031349 positive regulation of defense response GO:0032088 negative regulation of NF-kappaB transcription factor activity GO:0032479 regulation of type I interferon production GO:0032480 negative regulation of type I interferon production GO:0032606 type I interferon production GO:0034340 response to type I interferon GO:0034341 response to interferon-gamma GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0045341 MHC class I biosynthetic process GO:0045343 regulation of MHC class I biosynthetic process GO:0045345 positive regulation of MHC class I biosynthetic process GO:0045824 negative regulation of innate immune response GO:0050777 negative regulation of immune response GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051607 defense response to virus GO:0060330 regulation of response to interferon-gamma GO:0060332 positive regulation of response to interferon-gamma GO:0060333 interferon-gamma-mediated signaling pathway GO:0060334 regulation of interferon-gamma-mediated signaling pathway GO:0060335 positive regulation of interferon-gamma-mediated signaling pathway GO:0060337 type I interferon signaling pathway GO:0060338 regulation of type I interferon-mediated signaling pathway GO:0060339 negative regulation of type I interferon-mediated signaling pathway GO:0060340 positive regulation of type I interferon-mediated signaling pathway GO:0060759 regulation of response to cytokine stimulus GO:0060760 positive regulation of response to cytokine stimulus GO:0060761 negative regulation of response to cytokine stimulus GO:0071346 cellular response to interferon-gamma GO:0071357 cellular response to type I interferon GO:0098542 defense response to other organism
Molecular Function	GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding GO:0001046 core promoter sequence-specific DNA binding GO:0001047 core promoter binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-936440: Negative regulators of RIG-I/MDA5 signaling R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways

Summary
Symbol	NLRC5
Name	NLR family, CARD domain containing 5
Aliases	NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location	16q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NLRC5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between NLRC5 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27162338	Pan-Cancer	Promote immunity (infiltration)	Strikingly, NLRC5 expression was significantly associated with the activation of CD8(+) cytotoxic T cells and patient survival in multiple cancer types.

Summary
Symbol	NLRC5
Name	NLR family, CARD domain containing 5
Aliases	NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location	16q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NLRC5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: 1.48; FDR: 0.000150	Sensitive to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NLRC5
Name	NLR family, CARD domain containing 5
Aliases	NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location	16q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NLRC5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.218	0.521
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.459	0.746
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.053	0.953
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.35	0.415
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.257	0.921
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.477	0.894
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.581	0.213
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.054	0.463
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.049	0.976
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.371	0.347
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.565	0.484
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.118	0.466

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NLRC5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	8.2	2.9	0.699
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	8.5	2.6	0.702
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	5.9	3.6	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	12.5	-1.4	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	22.2	-22.2	0.505
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	7.4	-2.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	7.7	1.4	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	NLRC5
Name	NLR family, CARD domain containing 5
Aliases	NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location	16q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NLRC5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NLRC5
Name	NLR family, CARD domain containing 5
Aliases	NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location	16q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NLRC5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NLRC5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NLRC5
Name	NLR family, CARD domain containing 5
Aliases	NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location	16q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NLRC5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NLRC5
Name	NLR family, CARD domain containing 5
Aliases	NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location	16q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NLRC5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NLRC5
Name	NLR family, CARD domain containing 5
Aliases	NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location	16q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NLRC5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NLRC5
Name	NLR family, CARD domain containing 5
Aliases	NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location	16q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NLRC5 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NLRC5